The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations
Abstract
The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. The present publication represents a consensus document from questionnaires and consensus meetings held during 2017. The issues tackled in the project dealt with: infectious risk assessment, risk management and prophylaxis, intravenous immunoglobulin replacement therapy, antiviral and antibacterial vaccination. Considering the lack of conclusive and/or enough large studies for certain topics several recommendations derived from the personal experience of the experts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citation2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit816 · Cited by 1,037
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
The Delphi technique: a methodological discussion
Williams, P. L., & Webb, C. (1994) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.1994.tb01066.x · Cited by 929
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Self-citationCavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Self-citationMiguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationSan-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Self-citationAverbuch, D., Orasch, C., Cordonnier, C., Livermore, D. M., Mikulska, M., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G., Marchetti, O., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091025 · Cited by 632
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C., Holmberg, E., Mellqvist, U.-H., Landgren, O., Bjorkholm, M., Hultcrantz, M., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2015) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 524
Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Loomba, R., Rowley, A., Wesley, R., Liang, T. J., Hoofnagle, J. H., Pucino, F., & Csako, G. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-7-200804010-00008 · Cited by 459
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Self-citationUsing the Nominal Group Technique: how to analyse across multiple groups
McMillan, S. S., Kelly, F., Sav, A., Kendall, E., King, M. A., Whitty, J. A., & Wheeler, A. J. (2014) · Health Services and Outcomes Research Methodology · doi:10.1007/s10742-014-0121-1 · Cited by 356
Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00389-7 · Cited by 314
Self-citationMoreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355081 · Cited by 303
Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Brechignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0002 · Cited by 202
Robertson, J. D., Nagesh, K., Jowitt, S. N., Dougal, M., Anderson, H., Mutton, K., Zambon, M., & Scarffe, J. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1088 · Cited by 199
Mikulska, M., Averbuch, D., Tissot, F., Cordonnier, C., Akova, M., Calandra, T., Ceppi, M., Bruzzi, P., Viscoli, C., Akova, M., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2017.10.009 · Cited by 198
Self-citationGirmenia, C., Rossolini, G. M., Piciocchi, A., Bertaina, A., Pisapia, G., Pastore, D., Sica, S., Severino, A., Cudillo, L., Ciceri, F., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.231 · Cited by 189
Self-citationBackhaus, E., Berg, S., Andersson, R., Ockborn, G., Malmström, P., Dahl, M., Nasic, S., & Trollfors, B. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1648-2 · Cited by 174
Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix690 · Cited by 168
Self-citationCommunity-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Niesvizky, R., Flinn, I. W., Rifkin, R. M., Gabrail, N. Y., Charu, V., Clowney, B., Essell, J. H., Gaffar, Y., Warr, T. A., Neuwirth, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.7618 · Cited by 162
Averbuch, D., Cordonnier, C., Livermore, D. M., Mikulska, M., Orasch, C., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G., Marchetti, O., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091330 · Cited by 158
Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 150
Mallet, V. O., van Bömmel, F., Doerig, C., Pischke, S., Hermine, O., Locasciulli, A., Cordonnier, C., Berg, T., Moradpour, D., Wedemeyer, H. H., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00118-3 · Cited by 147
Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis
Cheng, M. P., Chakra, C. N. A., Yansouni, C. P., Cnossen, S., Shrier, I., Menzies, D., & Greenaway, C. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw838 · Cited by 140
Gay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 133
Self-citationTeh, B. W., Harrison, S. J., Worth, L. J., Spelman, T. D., Thursky, K., & Slavin, M. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13532 · Cited by 130
Management of multiple myeloma in the newly diagnosed patient
Mateos, M., & Miguel, J. F. S. (2017) · Hematology · doi:10.1182/asheducation-2017.1.498 · Cited by 108
Hulin, C., Belch, A. R., Shustik, C., Petrucci, M. T., Dührsen, U., Lu, J., Song, K., Rodon, P., Pegourié, B., Garderet, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7295 · Cited by 88
Self-citationNavigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabó, Z. R., & Garderet, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 86
Vesole, D. H., Oken, M. M., Heckler, C. E., Greipp, P. R., Katz, M. S., Jacobus, S. J., & Morrow, G. R. (2012) · Leukemia · doi:10.1038/leu.2012.124 · Cited by 79
Teh, B. W., Teng, J. C., Urbancic, K. F., Grigg, A., Harrison, S. J., Worth, L. J., Slavin, M. A., & Thursky, K. (2014) · Haematologica · doi:10.3324/haematol.2014.114025 · Cited by 77
Teh, B. W., Harrison, S. J., Worth, L. J., Thursky, K., & Slavin, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.025 · Cited by 71
Role of Gamma Globulin for Immunoprophylaxis in Multiple Myeloma
Salmon, S. E., Samal, B. A., Hayes, D. M., Hosley, H. F., Miller, S. P., & Schilling, A. (1967) · New England Journal of Medicine · doi:10.1056/nejm196712212772503 · Cited by 68
Hahn, M., Schnitzler, P., Schweiger, B., Kunz, C., Ho, A. D., Goldschmidt, H., & Schmitt, M. W. (2015) · Haematologica · doi:10.3324/haematol.2014.116772 · Cited by 64
Palazzo, M. A., Shah, G. L., Copelan, O. R., Seier, K. P., Devlin, S. M., Maloy, M., Kenny, S., Hassoun, H., Korde, N., Lendvai, N. K., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.795 · Cited by 63
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
Oliva, S., Troia, R., D’Agostino, M., Boccadoro, M., & Gay, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02749 · Cited by 61
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau, P., van de Donk, N. W. C. J., Miguel, J. F. S., Lokhorst, H. M., Nahi, H., Ben‐Yehuda, D., Cavo, M., Cook, G., Delforge, M., Einsele, H., et al. (2016) · Drugs · doi:10.1007/s40265-016-0573-4 · Cited by 48
Self-citationBranagan, A. R., Duffy, E. J., Albrecht, R. A., COOPER, D. L., Seropian, S., Parker, T. L., Gan, G., Li, F., Zelterman, D. A., Boddupalli, C. S., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.025 · Cited by 48
Emerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 46
Li, J., Huang, B., Li, Y., Zheng, D., Zhou, Z., & Liu, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.941833 · Cited by 42
Teh, B. W., Worth, L. J., Harrison, S. J., Thursky, K., & Slavin, M. A. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2550-3 · Cited by 41
Blombery, P. A., Prince, H. M., Worth, L. J., Main, J., Yang, M., Wood, E. M., & Westerman, D. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1275-3 · Cited by 39
König, C., Kleber, M., Reinhardt, H., Knop, S. T., Wäsch, R., & Engelhardt, M. M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1951-6 · Cited by 36
Hinge, M., Ingels, H. A. S., Slotved, H., & Mølle, I. (2012) · Apmis · doi:10.1111/j.1600-0463.2012.02922.x · Cited by 35
Post-splenectomy thrombosis and haemolytic anaemias.
Kemahli, S., Canatan, D., Cin, S., Uysal, Z., Akar, N., & Arcasoy, A. (1997) · PubMed · Cited by 34
Vaccination in Multiple Myeloma: Review of Current Literature
Alemu, A., Richards, J. O., Oaks, M. K., & Thompson, M. A. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.06.006 · Cited by 31
Offidani, M., Corvatta, L., Polloni, C., Gentili, S., Brioni, A., Visani, G., Galieni, P., Brunori, M., Alesiani, F., Catarini, M., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.555027 · Cited by 30
Self-citationPark, S., Jung, C. W., Jang, J. H., Kim, S. J., Kim, W. S., & Kım, K. (2015) · Transplant Infectious Disease · doi:10.1111/tid.12424 · Cited by 28
Kim, J., Min, C., Mun, Y., Park, Y., Kim, B. S., Nam, S.-H., Koh, Y., Kwon, J., Choe, P. G., Park, W. B., et al. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.10.018 · Cited by 27
Cytomegalovirus reactivation in patients with multiple myeloma
Hasegawa, T., Aisa, Y., Shimazaki, K., Ito, C., & Nakazato, T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12551 · Cited by 25
Jung, S., Bae, S.-Y., Ahn, J., Kang, S., Yang, D., Kim, Y., Kim, H., & Lee, J. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1270-7 · Cited by 24
Kamber, C., Zimmerli, S., Suter‐Riniker, F., Mueller, B. U., Taleghani, B. M., Betticher, D. C., Zander, T., & Pabst, T. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.290 · Cited by 24
Jung, S., Kang, S., Jang, H., Ahn, J., Yang, D., Lee, S.-S., Kim, Y., Kim, H., & Lee, J. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1672-1 · Cited by 22
Marchesi, F., Pimpinelli, F., Dessanti, M. L., Gumenyuk, S., Palombi, F., Pisani, F., Romano, A., Spadea, A., Maschio, M. C. E., Ensoli, F., et al. (2014) · Transplant Infectious Disease · doi:10.1111/tid.12309 · Cited by 20
Caravita, T., Offidani, M., Siniscalchi, A., Gentili, S., Caraffa, P., Perrotti, A. P., de Fabritiis, P., & Leoni, P. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01814.x · Cited by 17
Self-citationLiu, J., Huang, H., Li, Y., Liu, L., Li, J., Liu, Z., Lu, J., Ouyang, J., Song, Y., Zhou, D., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4441-8 · Cited by 16
Varma, A., Biritxinaga, L., Saliba, R. M., Stich, M., Jauch, S. F., Afrough, A., Honhar, M., Popat, U., Shafi, M. A., Shah, N. D., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.005 · Cited by 16
Hyun, S. Y., Han, S. H., Kim, S., Jang, J. E., Kim, Y., Cho, H., Lee, J. Y., Cheong, J., Min, Y. H., Song, J., et al. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.4.510 · Cited by 15
A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease
Teh, B. W., Khot, A. S., Harrison, S. J., Prince, H. M., & Slavin, M. A. (2013) · Transplant Infectious Disease · doi:10.1111/tid.12106 · Cited by 13
Wondergem, M. J., Grünberg, K., Wittgen, B. P. H., Sonneveld, P., & Zweegman, S. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03263.x · Cited by 10
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
Rafei, H., Haroun, F., & Tabbara, I. A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000506 · Cited by 10
CYTOMEGALOVIRUS RETINITIS AFTER TREATMENT WITH LENALIDOMIDE FOR MULTIPLE MYELOMA
Lim, H. Y., Francis, D., Yeoh, J., & Lim, L. L. (2013) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e31827aee62 · Cited by 8
The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma
Cornell, R. F., & Costa, L. J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.009 · Cited by 6
Kım, K., Kim, S. J., & Maeng, C. H. (2013) · Blood Research · doi:10.5045/br.2013.48.3.233 · Cited by 4
Cited by
Terpos, E., Engelhardt, M., Cook, G., Gay, F., Mateos, M.-V., Ntanasis-Stathopoulos, I., van de Donk, N. W. C. J., Avet-Loiseau, H., Hajek, R., Vangsted, A. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0876-z · Cited by 736
Usmani, S. Z., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Gavriatopoulou, M., Oriol, A., Rabin, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00579-9 · Cited by 171
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
(2018) · PubMed · Cited by 4
Metadata
- Authors
- Girmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Di Raimondo, F., Musto, P., Petrucci, M. T., & Barosi, G.
- Venue
- Blood Reviews
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 34
- Pages
- 84-94
- ISSN
- 0268-960X (ISSN-L)
- OpenAlex
- W2909894833
- Cited by
- 662
- References
- 79
- FWCI
- 30.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.